Method for producing product
By controlling poloxamer and product concentrations, and hydrophobicity indices in perfusion culture, the issue of membrane clogging is addressed, enhancing productivity and culture duration in biopharmaceutical production.
Patent Information
- Application Number
- PCT/JP2024/019989
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-05
AI Technical Summary
Perfusion culture in biopharmaceutical production often leads to membrane clogging due to antibody and poloxamer aggregation, resulting in reduced productivity and culture duration.
Control the poloxamer concentration, product concentration, hydrophobicity index SAP value, and valine residues in the L chain variable region to maintain specific ratios, preventing aggregation and membrane clogging through optimized perfusion culture conditions.
This approach effectively suppresses membrane clogging and maintains high productivity by controlling the concentrations and properties of antibodies and poloxamers, allowing for extended culture periods and higher viable cell densities.
Smart Images

Figure JPOXMLDOC01-APPB-I000002 
Figure JPOXMLDOC01-APPB-I000004 
Figure JPOXMLDOC01-APPB-T000001
Abstract
Description
How the product is produced
[0001] The present invention relates to a method for producing a product, which comprises culturing cells in a culture medium.
[0002] Cell culture is carried out for the purpose of increasing the number of cells with useful properties, causing cells to produce products, etc. In the production of biopharmaceuticals such as antibodies, perfusion culture is often used to improve antibody productivity, in which the culture medium is continuously filtered and discharged while fresh medium containing nutrients is continuously supplied to the culture vessel.
[0003] For example, Patent Document 1 describes a method for producing a bispecific antibody product, comprising the steps of: (i) providing at least one mammalian cell capable of expressing a bispecific antibody product in a perfusion bioreactor; (ii) growing the mammalian cell culture at a first perfusion rate until a set viable cell density is reached; and (iii) maintaining the perfusion culture at a second perfusion rate, wherein the bispecific antibody product concentration in the bioreactor is maintained below a threshold value.
[0004] Special Publication No. 2021-505182
[0005] Perfusion culture has attracted attention as a production method for improving the productivity of antibody pharmaceuticals. In perfusion culture, membrane filtration is often used as a means for continuously separating cells, but there is a problem that the membrane clogs during culture, making it impossible to culture for the desired period and reducing productivity. The problem to be solved by the present invention is to provide a method for producing products by cell culture that can prevent membrane clogging during culture and prevent a decrease in productivity.
[0006] As a result of extensive research to solve the above problems, the present inventors discovered that membrane blockage can be suppressed by appropriately controlling the hydrophobicity index SAP of the antibody, the antibody concentration in the culture medium, and the poloxamer concentration in the culture medium, and thus completed the present invention.
[0007] That is, the present invention provides the following inventions: <1> A method for producing a product, comprising culturing cells in a culture medium, wherein at least one of the following is satisfied: 1.5P + 3C + 0.93S ≦ 378 (Equation 1) or P + 3.5C + 1.9V ≦ 29 (Equation 5), where P (g / L) is the poloxamer concentration in the culture medium, C (g / L) is the product concentration in the culture medium, S is the hydrophobicity index SAP value of the product, and V (%) is the proportion of valine residues in the L-chain variable region of the product. <2> A method for producing a product according to <1>, wherein the poloxamer concentration P (g / L) satisfies 1.5 ≦ P ≦ 15 (Equation 2). <3> A method for producing a product according to <1> or <2>, wherein the product concentration C (g / L) satisfies 0.2 ≦ C ≦ 10 (Equation 3). <4> A method for producing the product according to any one of <1> to <3>, wherein the hydrophobicity index SAP value S satisfies the following: 300≦S≦394 (Equation 4). <5> A method for producing the product according to any one of <1> to <4>, wherein the ratio V (%) satisfies the following: 0≦V≦9 (Equation 6). <6> A method for producing the product according to any one of <1> to <5>, wherein the culture is perfusion culture. <7> A method for producing the product according to <6>, wherein the perfusion culture includes a cell separation step of separating cells using a filtration membrane. <8> A method for producing the product according to <7>, wherein the cell separation step is performed using an ATF method, which is an alternating tangential flow. <9> A method for producing the product according to any one of <6> to <8>, wherein, after a target viable cell density is reached in the culture, the product is produced for a certain period of time while maintaining the viable cell density substantially constant during the perfusion culture. <10> The viable cell density maintained constant is 30 x 10 6 cells / ml or more 400×10 6<11> A method for producing the product according to any one of <6> to <10>, wherein the perfusion ratio in the perfusion culture is 0.3 or more and 3.0 or less. <12> A method for producing the product according to any one of <1> to <11>, wherein the culture period is 14 days or more and 200 days or less. <13> A method for producing the product according to any one of <1> to <12>, wherein the cells are CHO cells. <14> A method for producing the product according to any one of <1> to <13>, wherein the product is a protein. <15> A method for producing the product according to <14>, wherein the protein is an antibody. <16> A method for producing the product according to <15>, wherein the light chain structure of the antibody is κ type.
[0008] According to the method for producing a product of the present invention, clogging of the membrane during the cultivation can be prevented, and a decrease in productivity can be prevented.
[0009] Figure 1 shows a cell culture device. Figure 2 shows the results of measuring viable cell density. Figure 3 shows the results of measuring ATF reciprocating pressure. Figure 4 shows the results of measuring antibody permeability. Figure 5 shows the results of measuring titer.
[0010] The present invention will be described in detail below. In this specification, a numerical range indicated using "to" means a range that includes the numerical values before and after "to" as the minimum and maximum values, respectively.
[0011] The method for producing a product of the present invention comprises culturing cells in a culture medium, and satisfies at least one of the following: 1.5P + 3C + 0.93S ≦ 378 (Equation 1) or P + 3.5C + 1.9V ≦ 29 (Equation 5), where P (g / L) is the poloxamer concentration in the culture medium, C (g / L) is the product concentration in the culture medium, S is the hydrophobicity index SAP value of the product, and V (%) is the proportion of valine residues in the L-chain variable region of the product.
[0012] The method for producing a product of the present invention can be suitably used as a method for producing a product by cell culture used in biopharmaceuticals, regenerative medicine, etc.
[0013] Preferably, P, C, and S satisfy the following formula: 340≦1.5P+3C+0.93S≦370 (Formula 1A). Preferably, P, C, and V satisfy the following formula: P+3.5C+1.9V≦23 (Formula 5A).
[0014] By setting 1.5P+3C+0.93S to 378 or less, or by setting P+3.5C+1.9V to 29 or less, aggregation of the antibody and poloxamer can be suppressed, and membrane clogging can be prevented.
[0015] The poloxamer concentration P (g / L) in the culture medium preferably satisfies the following formula: 1.5≦P≦15 (Formula 2).
[0016] When the poloxamer concentration P is 1.5 g / L or higher, the cell protective effect of the poloxamer allows cells to grow favorably and also suppresses the generation of cell debris. When the poloxamer concentration P is 15 g / L or lower, aggregation of the antibody and poloxamer can be suppressed, preventing membrane clogging.
[0017] From the viewpoint of suppressing aggregate formation, the poloxamer concentration is preferably 1.5 g / L or more but less than 6 g / L (preferably 2.0 g / L or more but less than 5.8 g / L, more preferably 3.0 g / L or more but less than 5.5 g / L, and even more preferably 4.0 g / L or more but less than 5.5 g / L). From the viewpoint of cell protective effect, the poloxamer concentration is preferably 6 g / L or more but less than 15 g / L (preferably 7 g / L or more but less than 14 g / L, more preferably 8 g / L or more but less than 13 g / L, and even more preferably 9 g / L or more but less than 12 g / L). In this case, the amount of aggregates increases, but this is effectively suppressed by the present invention.
[0018] The culture medium contains both cells and culture supernatant. The poloxamer concentration in the culture medium can be measured by the following method. A culture medium sample is removed from the culture vessel, the cells are filtered, and the filtrate is collected. 1.17 g of maleic acid (special reagent grade, Fujifilm Wako Pure Chemical Industries, Ltd.) is added to 50 ml of deuterium oxide and dissolved. 0.4 ml of heavy water containing 20, 50, 100, or 200 mg of Kolliphor P188 (BASF) is added to 1.6 ml of heavy water containing maleic acid, and the mixture is measured by 1H NMR (400 MHz, Ascend 400, Bruker) with 64 cumulative measurements. Using the maleic acid peak at 6.2 ppm as the standard, a calibration curve is drawn using poloxamer peak 1 (around 0.8-1.1 ppm) and peak 2 (around 3.4-3.5 ppm). 0.4 ml of culture supernatant is added to 1.6 ml of maleic acid-containing heavy water, and 1H NMR is measured at an integrated frequency of 64 times, and quantification is performed from the area ratio of peak 1 or peak 2 to maleic acid. Either peak 1 or peak 2 is used depending on the level of impurities.
[0019] The product concentration C (g / L) preferably satisfies the following formula: 0.2≦C≦10 (formula 3).
[0020] When the product concentration C is 0.2 g / L or higher, the amount of antibody recovered increases, and high productivity can be maintained. When the product concentration C is 10.0 g / L or lower, aggregation of the antibody and poloxamer can be suppressed, and membrane clogging can be prevented.
[0021] The product concentration C is more preferably 0.2 g / L or more and 10.0 g / L or less, even more preferably 0.5 g / L or more and 5.0 g / L or less, and particularly preferably 1.0 g / L or more and 3.5 g / L or less.
[0022] The product can be purified by a purification treatment. The obtained product can be purified to a high purity. Separation and purification of the product can be performed using separation and purification methods commonly used for proteins. For example, the product can be separated and purified by appropriately selecting and combining chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, isoelectric focusing, etc., but is not limited to these. The concentration of the product obtained above can be measured by absorbance measurement or enzyme-linked immunosorbent assay (ELISA), etc. When the product is an antibody, the product concentration can be measured by extracting a sample from the culture vessel, filtering the cells with Whatman (Pore Size 0.2 μm, 25 mm Diameter) manufactured by Cytiva, and then measuring the filtrate with Cedex Bio manufactured by Roche.
[0023] The hydrophobicity index SAP value S preferably satisfies the following expression: 300≦S≦394 (Equation 4).
[0024] A protein structure suitable for therapeutic use can be obtained when the SAP value is 300 or higher. By setting the SAP value to 394 or lower, aggregation of the antibody and poloxamer can be suppressed, and membrane clogging can be prevented.
[0025] The SAP value is more preferably 350 or more and less than 394, and even more preferably 350 or more and 390 or less.
[0026] The SAP value (Spatial Aggregation Propensity) is an index of how many hydrophobic amino acids (such as valine, leucine, alanine, etc.) are aggregated on the surface of a protein.
[0027] The SAP value can be determined by the following procedure. (1) Predicting the three-dimensional structure of a protein. The software AlphaFold2 can be used to predict the three-dimensional structure of a protein (in the examples of this application, training data up to 2021-07-14 was used). In addition to AlphaFold2, software such as MOE, Schrodinger, and BIOVIA Discovery Studio can also be used. In the case of antibodies, the Fab and Fc regions can be predicted separately, or the Fab and Fc regions can be predicted at the same time. In the examples of this application, the Fab and Fc regions were predicted separately.
[0028] (2) For IgG1 antibodies, Fab and Fc are aligned using the 1hzh crystal structure from the Protein Data Bank as a reference, and for IgG2 and IgG4 antibodies, structures created by modifying the 1hzh crystal structure are used as a reference. Software such as MOE, Schrodinger, BIOVIA Discovery Studio, Pymol, and TM-align can be used to calculate the structural alignment.
[0029] (3) Structural optimization using molecular dynamics is performed while applying a stress between the CYS disulfide bonds according to the antibody structure, and bond formation is achieved. (4) Molecular dynamics calculations are performed to obtain a stable equilibrated antibody structure. Software such as Amber, Ambertools, and Gromacs can be used for CYS bond formation and molecular dynamics calculations.
[0030] (5) The SAP value is calculated according to the following publication: Naresh Chennamsetty (2009), Design of therapeutic proteins with enhanced stability, Proc Natl Acad Sci USA. 2009 Jul 21; 106(29): 11937-42. Note that the residue hydrophobicity, the hydrophobicity value specific to amino acids, was calculated using the values described in the following publication: Shaun D. Black (1991), Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications, Analytical Biochemistry Volume 193, Issue 1, 15 February 1991, Pages 72-82. Software such as MOE or BIOVIA Discovery Studio can be used to calculate the SAP value. The SAP values of each antibody listed in Table 1 in the Examples were calculated using the above method.
[0031] The sum of SAPs can predict aggregation risk.
[0032] The proportion V (%) of valine residues in the L-chain variable region of the product preferably satisfies the following formula: 0≦V≦9 (Formula 6).
[0033] By setting V to 9 or less, aggregation of the antibody and poloxamer can be suppressed, and membrane clogging can be prevented.
[0034] V is more preferably 0 or more and 9 or less, even more preferably 0 or more and 8 or less, and most preferably 0 or more and 7 or less.
[0035] V is an index of the ratio of valine residues, a hydrophobic amino acid, in the L chain variable region.
[0036] V can be calculated using the following procedure. The L-chain variable region of an antibody is defined as the region obtained by excluding 70 residues from the C-terminus of the antibody L chain (the side with a carboxyl group at the end), and the percentage of valine residues among the total amino acid residues in that region is defined as the V value. When the left and right chains differ, as in the case of bispecific antibodies, each is calculated separately. In this case, aggregation does not occur if both conditions are met. Aggregation occurs if either condition is not met. Furthermore, when an L chain is originally composed of L chains from two or more different antibodies linked together, i.e., in special cases where the original L-chain variable region is introduced at two or more locations in the L chain, rather than calculating the valine residues at the original L-chain variable region site, the L-chain variable region is defined as the region obtained by excluding 70 residues from the C-terminus of the L chain from the entire L chain, and the percentage of valine residues among the total amino acid residues in that region is defined as the V value, as in the calculation method for conventional antibodies described above. The V values for each antibody listed in Table 1 in the Examples were calculated using the above method.
[0037] The valine ratio V in the L chain variable region can be used to predict aggregation risk.
[0038] The culture in the present invention is preferably perfusion culture. Perfusion culture is a culture method in which fresh medium is added and spent medium is simultaneously removed. Perfusion culture generally allows for a high viable cell density to be achieved. A typical perfusion culture begins with a batch culture start-up lasting one or two days, after which fresh feed medium is continuously, stepwise, and / or intermittently added to the culture, and spent medium is simultaneously removed. In perfusion culture, spent medium can be removed while maintaining viable cell density using methods such as sedimentation, centrifugation, or filtration. An advantage of perfusion culture is that the culture in which the target protein is produced can be maintained for a longer period of time than batch or fed-batch culture.
[0039] Perfusion can be continuous, stepwise, intermittent, or a combination thereof, preferably continuous. The animal cells are maintained in culture, and the removed spent medium may be substantially cell-free or contain far fewer cells than the culture. The product expressed by the cell culture can be maintained in culture or recovered by selecting the membrane pore size.
[0040] The period of perfusion culture is preferably 5 to 300 days, more preferably 14 to 200 days, even more preferably 14 to 100 days, and even more preferably 20 to 90 days. A culture period of 5 days or more is preferred because it increases the number of cells obtained and, if the cells produce a product, increases the amount of product produced. A culture period of 300 days or less is preferred from the viewpoint of preventing clogging of the filtration membrane used in perfusion culture and preventing contamination.
[0041] The perfusion culture preferably includes a cell separation step in which cells are separated using a filtration membrane. The cell separation step is preferably performed using an ATF method, which is an alternating tangential flow method.
[0042] The perfusion ratio is not particularly limited, but is preferably 0.3 vvd or more and 3.0 vvd or less, more preferably 0.6 vvd or more and 2.5 vvd or less, and even more preferably 0.8 vvd or more and 2.0 vvd or less.
[0043] A perfusion ratio of 0.3 or higher prevents the antibody from becoming highly concentrated, inhibits aggregation of the antibody and poloxamer, and prevents membrane clogging. A perfusion ratio of 3.0 or lower effectively reduces the amount of medium used.
[0044] The perfusion ratio (vvd) refers to the volume of culture medium extracted / volume of culture medium in the culture vessel / day. Note that the perfusion ratio here is a different parameter from the example of bleeding, "(iv) When the capacitance of the culture medium exceeds the target, operate the pump extracting the culture medium at a speed of 0.3 vvd to 3 vvd."
[0045] The culture medium is usually removed from the culture vessel using a pump, but other available liquid-transporting means may also be used. The culture medium removed from the culture vessel is then subjected to treatments such as product recovery and dead cell removal. After product recovery and dead cell removal, the culture medium removed from the culture vessel may be partially discarded or returned to the culture vessel. If a loss of medium occurs due to the above treatments, it can be compensated for by, for example, supplying fresh medium to the culture vessel.
[0046] Preferably, perfusion culture involves producing a product for a certain period of time while maintaining a substantially constant viable cell density after the target viable cell density is reached in the culture. "Maintaining a substantially constant viable cell density" means that the viable cell density is maintained within ±20%, preferably within ±10%, more preferably within ±5%, and even more preferably within ±3% of the target viable cell density.
[0047] The viable cell density, which remains substantially constant, is 30 x 10 6 cells / ml or more 400×10 6 It is preferable that the concentration is 30×10 6 cells / ml or more 300×10 6 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 240×10 6 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 200×10 6 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 160×10 6 More preferably, the concentration is 100×10 6 cells / ml or more 160×10 6 More preferably, the concentration is 100×10 6 cells / ml or more 120×10 6 It is particularly preferable that the concentration is 10 cells / ml or less. 6 It is sometimes written as M instead of .
[0048] The viable cell density was 30 x 10 6 By increasing the viable cell density to 400 x 10 cells / ml or more, the amount of antibody recovered increases and high productivity can be maintained. 6 By keeping the concentration at 1000 cells / ml or less, aggregation of the antibody and poloxamer can be suppressed, and clogging of the membrane can be prevented.
[0049] Viable cell density can be measured using a commercially available measuring device such as Beckman Coulter's Cell Viability Analyzer Vi-cell XR. For example, the Vi-cell software Vi-cell XR2.04 can be used, and the measurement parameters can be set as follows: Min diameter: 6 μm, Max diameter: 50 μm. Cell brightness: 85% Cell sharpness: 100 Viable cell spot brightness: 75% Viable cell spot area: 5% Minimum circularity:0 Decluster degree:Medium
[0050] In the present invention, preferably, in order to maintain a substantially constant viable cell density, cell bleeding (also called bleeding) is carried out by discharging the culture medium containing the cells from the system and adding a medium.
[0051] The cell bleed ratio in the cell bleed is preferably 0.10 to 0.80 vvd, more preferably 0.15 to 0.60 vvd.
[0052] By setting the cell bleed rate to 0.10 vvd or higher, growth can be maintained appropriately and antibody quality can be stably maintained. By setting the cell bleed rate to 0.80 vvd or lower, the amount of medium used can be reduced, thereby reducing costs.
[0053] Bleeding can be performed by any method as long as the culture solution containing the cells can be removed from the culture vessel. For example, as shown in Figure 1, a pipe for discharging the culture solution can be inserted into the culture solution, and the culture solution can be discharged from the culture vessel through the pipe.
[0054] Preferably, the culture medium may be bled while measuring the capacitance of the culture medium in-line. In-line measurement refers to measuring some measurement value that indicates the state of the culture medium while cell culture is being performed. To measure the capacitance in-line, for example, as shown in FIG. 1, a capacitance sensor may be inserted into the culture medium, and the capacitance of the culture medium may be measured in-line during culture.
[0055] Preferably, the bleeding may be automatically controlled. Automatic control means that the start and stop of bleeding are automatically controlled based on some measured value indicating the state of the culture solution. For example, the start and stop of bleeding can be automatically controlled based on a measured value of the capacitance of the culture solution.
[0056] Preferably, bleeding may be performed so that the variation in the capacitance of the culture medium measured inline is ±20% or less of the average capacitance during the production period. The variation in the capacitance of the culture medium measured inline is more preferably ±15% or less of the average capacitance during the production period, even more preferably ±12% or less of the average capacitance during the production period, and particularly preferably ±8% or less of the average capacitance during the production period. The lower limit of the variation in the capacitance of the culture medium is not particularly limited, and it is sufficient if it is 0% or more, but considering daily fluctuations in cell growth, variation of 0.1% or more will actually occur.
[0057] An example of bleeding can be performed by the steps of: (i) setting a target capacitance; (ii) setting a weight control value for the culture vessel; (iii) measuring the capacitance of the culture solution at a period of 0.1 seconds or less; (iv) when the capacitance of the culture solution exceeds the target, operating a pump that extracts the culture solution at a speed of 0.3 vvd to 3 vvd (where vvd means volume of culture solution extracted / volume of culture solution / day); (v) automatically supplying medium to the culture vessel while measuring the mass of the culture solution so that the fluctuation in the liquid volume of the culture solution is within 10%; and (vi) stopping the pump that extracts the culture solution when the capacitance of the culture solution falls below the target by 0.01% or more.
[0058] An example of a cell culture device that can be used for culturing cells in the present invention is shown in Figure 1. In Figure 1, a culture vessel 10 is a vessel that contains a culture medium containing cells. Cells are cultured in the culture medium inside the culture vessel 10.
[0059] Oxygen and air are sent from the sparger air supply pipe 1 and introduced into the culture solution through a sparger 11 having a pore size of 20 μm. The dissolved oxygen concentration in the culture solution can be adjusted by the sparger 11. The sparger is not particularly limited, but for example, a sparger having an average pore size of 1 μm or more and 300 μm or less in the gas release section and releasing a gas containing 30% by volume or more of oxygen can be used.
[0060] Air and carbon dioxide are introduced from the air supply pipe 2 into the upper part of the culture solution inside the culture vessel. Culture medium is supplied to the culture vessel from the culture medium supply pipe 3. A culture medium supply pump 15 is provided on the culture medium supply pipe 3. The exhaust pipe 4 is a pipe for exhausting air, and an exhaust filter 5 is connected to its end. The sampling pipe 6 is a pipe for collecting (sampling) the culture solution. The bleeding pipe 7 is a pipe for extracting (bleeding) the culture solution. A capacitance sensor 8 is attached so as to come into contact with the culture solution in the culture vessel. A dissolved oxygen sensor 9 is attached so as to come into contact with the culture solution in the culture vessel.
[0061] A stirring member having a stirring blade 12 may be provided inside the culture vessel 10. By rotating the stirring blade 12, the culture solution inside the culture vessel 10 is stirred, maintaining the homogeneity of the culture solution. The stirring of the culture solution by the stirring blade 12 also stirs the bubbles released by the sparger. The position of the stirring member having the stirring blade, the size of the stirring blade, etc. are not particularly limited and may be designed depending on the cell type used, the amount of culture solution, the amount of oxygen supplied, the position, number, size, etc. of the sparger. Furthermore, in order to quickly stir the bubbles coming out of the sparger and prevent the bubbles from coalescing, it is preferable to position the stirring blade 12 close to the sparger. Figure 1 shows the presence of foam 19.
[0062] A perfusion device 13 is connected to the bottom of the culture vessel 10. The culture solution inside the culture vessel 10 passes through the perfusion device 13 (hollow fiber MF membrane), and the permeate containing the cell product is removed from the culture vessel 10 by a delivery pump 16. The flow of the permeate is indicated by arrows 14. The perfusion device 13 may be equipped with a pressure gauge 17 and a diaphragm pump 18.
[0063] In the present invention, the cell suspension removed from the culture vessel may be passed through a separation membrane to separate it into a cell-containing solution and a permeate. This operation can be performed using a perfusion device. In this operation, the cell suspension removed from the culture vessel is separated into a cell-containing solution having a higher cell density than the cell suspension and a permeate having a lower cell density than the cell suspension. The cell density can be measured using a Vi-CELL XR viable cell analyzer manufactured by Beckman Coulter.
[0064] The membrane separation process is preferably tangential filtration, more preferably alternating tangential flow (ATF) or tangential flow, and most preferably ATF. Filters that can be used for ATF include SuATF10-S02PES and F2 RF02PES manufactured by Repligen.
[0065] As a medium for cell culture, a medium that is commonly used for culturing animal cells can be used. For example, CD OptiCHO (ThermoFisher), Dulbecco's Modified Eagle's Medium (DMEM), Eagle's Minimum Essential Medium (MEM), RPMI-1640 medium, RPMI-1641 medium, F-12K medium, Ham's F12 medium, Iscove's Modified Dulbecco's Medium (IMDM), McCoy's 5A medium, Leibovitz's L-15 medium, and EX-CELL™ 300 series (JRH Biosciences), CHO-S-SFMII (Invitrogen), CHO-SF (Sigma-Aldrich), CD-CHO (Invitrogen), IS CHO-V (Irvine Scientific), PF-ACF-CHO (Sigma-Aldrich), etc. may be used. Alternatively, a self-made medium may be used.
[0066] The medium may be supplemented with serum, such as fetal calf serum (FCS), or serum-free. The medium may be supplemented with additional components, such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements, plant protein hydrolysates, etc. Protein-free media may also be used.
[0067] The pH of the medium varies depending on the cells to be cultured, but is generally pH 6.0 to 8.0, preferably pH 6.4 to 7.6, and more preferably pH 6.7 to 7.4. The culture temperature is generally 30°C to 40°C, preferably 32°C to 39°C, and more preferably 36°C to 38°C, and the culture temperature may be changed during culture. The culture is carried out under CO 2 The process can be carried out in an atmosphere having a concentration of 0 to 40% by volume, preferably 2 to 25% by volume, and more preferably 3 to 20% by volume.
[0068] The amount of culture medium is preferably 1 L or more, more preferably 50 L or more, and even more preferably 200 L or more.
[0069] The culture period is not particularly limited, but is generally from 5 days to 300 days, preferably from 14 days to 200 days, more preferably from 14 days to 100 days, and even more preferably from 20 days to 90 days.
[0070] During the culture, the medium can be replaced, aerated, or stirred as necessary. When stirring is performed during the culture, the stirring speed is not particularly limited, but the stirring power per unit volume is generally 10 to 300 kW / m 3 and preferably 20 to 200 kW / m 3 and more preferably 30 to 100 kW / m 3 is.
[0071] The dissolved oxygen concentration in the culture solution can be set appropriately and is not particularly limited, but is generally 20 to 150%, preferably 30 to 120%, and more preferably 50 to 100%, when the saturated dissolved oxygen concentration in air at 1 atmosphere at 37°C is taken as 100%.
[0072] Cell culture can be carried out using a cell culture device having the configuration described above in this specification. The cell culture device may be any of a fermenter-type tank culture device, an airlift-type culture device, a culture flask-type culture device, a spinner flask-type culture device, a microcarrier-type culture device, a fluidized bed-type culture device, a hollow fiber-type culture device, a roller bottle-type culture device, or a packed tank-type culture device. From the viewpoint of homogenizing the culture environment, the culture vessel is preferably a single-use culture tank. From the viewpoint of homogenizing the culture environment, the cell culture device may also be a single-use culture tank.
[0073] The viscosity of the culture medium is preferably 1.2 mPa·s or more and less than 15 mPa·s, more preferably 1.4 mPa·s or more and less than 12 mPa·s, and particularly preferably 1.6 mPa·s or more and less than 10 mPa·s.
[0074] In the present invention, a pH adjuster may be added during the culture. In view of clogging of the filtration channel, the amount of pH adjuster added to the culture tank per day is preferably 8 mmol / day / L or less, more preferably 7 mmol / day / L or less. However, it is not necessary to add a pH adjuster. The pH adjuster is not particularly limited, but examples thereof include Na 2 CO 3 aqueous solution, aqueous NaOH or NaHCO 3 An aqueous solution is preferred, more preferably NaHCO 3 The pH adjuster may be added alone or mixed with the medium or antifoaming agent. To avoid local pH fluctuations in the culture solution due to the addition of the pH adjuster, it is preferable to add the pH adjuster to the medium.
[0075] The type of cell used in the present invention is not particularly limited, and examples include animal cells, plant cells, eukaryotic cells such as yeast, prokaryotic cells such as Bacillus subtilis, and Escherichia coli. The cells are preferably animal cells (more preferably mammalian cells) or insect cells, and most preferably mammalian cells. The cells may be primary cells or established cell lines.
[0076] Examples of cells include Chinese hamster ovary (CHO) cells, HEK cells (human embryonic kidney-derived cells), BHK cells, 293 cells, C127 cells, myeloma cells (such as NS0 cells), PerC6 cells, SP2 / 0 cells, hybridoma cells, COS cells (African green monkey kidney-derived cells), 3T3 cells, HeLa cells, Vero cells (African green monkey kidney epithelial cells), MDCK cells (canine kidney tubular epithelial cells), PC12 cells, and WI38 cells. The cells may also be stem cells such as embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS cells). Among these, CHO cells, HEK cells, BHK cells, and hybridoma cells are preferred, CHO cells and HEK cells are more preferred, and CHO cells are most preferred. CHO cells are widely used for the production of recombinant proteins, such as cytokines, coagulation factors, and antibodies. It is preferable to use dihydrofolate reductase (DHFR)-deficient CHO cells, and for example, CHO-DG44 can be used as the DHFR-deficient CHO cells.
[0077] The higher the cell viability, the better, with 80% or more being preferred, 85% or more being more preferred, 90% or more being particularly preferred, and 95% or more being most preferred.
[0078] These cells may be cells into which a foreign gene encoding a protein to be expressed (e.g., an antibody) has been introduced. Preferably, the cells are antibody-producing cells. An expression vector can be used to introduce a foreign gene encoding a protein to be expressed into a cell. By introducing an expression vector containing DNA encoding the protein to be expressed, an expression regulatory sequence (e.g., an enhancer, a promoter, a terminator, etc.), and optionally a selection marker gene into a cell, a cell into which a foreign gene encoding the protein to be expressed has been introduced can be produced. There are no particular limitations on the expression vector, and it can be selected and used appropriately depending on the type of cell, purpose, etc.
[0079] Any promoter can be used as long as it is functional in mammalian cells. Examples include the promoter of the cytomegalovirus (CMV) IE (immediate early) gene, the SV40 early promoter, retrovirus promoters, metallothionein promoters, heat shock promoters, SRα promoters, and promoters and enhancers of Moloney murine leukemia virus. Furthermore, an enhancer of the human CMV IE gene may also be used together with the promoter.
[0080] Examples of selectable marker genes that can be used include drug resistance genes (neomycin resistance gene, DHFR gene, puromycin resistance gene, blasticidin resistance gene, hygromycin resistance gene, cycloheximide resistance gene), and fluorescent genes (genes encoding green fluorescent protein (GFP) or the like).
[0081] The method for introducing an expression vector into cells is not particularly limited, and for example, the calcium phosphate method, electroporation, liposome method, gene gun method, lipofection method, etc. can be used.
[0082] The method for producing a product according to the present invention comprises culturing cells using a cell culture device and producing a product from the cells. The present invention also provides a product produced by the method for producing a product according to the present invention.
[0083] In the present invention, the type of product is not particularly limited, but is preferably a protein. Examples of the product include recombinant polypeptide chains, recombinant secreted polypeptide chains, antigen-binding proteins, antibodies (e.g., human antibodies, humanized antibodies, chimeric antibodies, mouse antibodies, bispecific antibodies, etc.), Fc fusion proteins, fragmented immune immunoglobulins, single-chain antibodies (scFv), etc. In addition, the product may be an adenovirus, an adeno-associated virus, a lentivirus, etc.
[0084] The product is preferably an antibody, more preferably a human antibody, a humanized antibody, a chimeric antibody, or a mouse antibody. Examples of fragmented immune immunoglobulins include Fab, F(ab')2, and Fv. The class of the antibody is not particularly limited, and may be any class, such as IgG (e.g., IgG1, IgG2, IgG3, and IgG4), IgA, IgD, IgE, or IgM, although IgG and IgM are preferred for pharmaceutical use. The light chain structure of the antibody may be either κ or λ, but is preferably κ.
[0085] Human antibodies include all antibodies that have one or more variable and constant regions derived from human immunoglobulin sequences, hi one embodiment, all of the variable and constant domains are derived from human immunoglobulin sequences (fully human antibodies).
[0086] A humanized antibody has a sequence that differs from that of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and / or additions, such that the humanized antibody is less likely to provoke an immune response and / or provokes a less severe immune response when administered to a human subject compared to the non-human species antibody. In one example, certain amino acids within the framework and constant domains of the heavy and / or light chains of the non-human species antibody are mutated to produce a humanized antibody. In another example, constant domains from a human antibody are fused to variable domains of the non-human species.
[0087] A chimeric antibody is an antibody in which variable and constant regions of different origins are linked. For example, an antibody consisting of the heavy and light chain variable regions of a mouse antibody and the heavy and light chain constant regions of a human antibody is a mouse-human heterochimeric antibody. A recombinant vector that expresses a chimeric antibody can be produced by linking DNA encoding the variable region of a mouse antibody to DNA encoding the constant region of a human antibody and incorporating this into an expression vector. Recombinant cells transformed with the above vector are cultured to express the incorporated DNA, thereby obtaining the chimeric antibody produced during the culture.
[0088] Bispecific antibodies are antibodies that recognize two different antigen specificities. Various forms of bispecific antibodies exist. Reported methods for producing bispecific antibodies include linking two immunoglobulin molecules using crosslinkers such as N-succinimidyl 3-(2-pyridyldithiol) propionate or S-acetylmercaptosuccinic acid anhydride, or linking Fab fragments of immunoglobulin molecules. Bispecific antibodies can also be expressed by introducing genes encoding them into cells.
[0089] An Fc fusion protein refers to a protein having an Fc region, including antibodies. Fab is a monovalent fragment having the VL, VH, CL, and CH1 domains. F(ab')2 is a bivalent fragment having two Fab fragments linked by a disulfide bridge at the hinge region. An Fv fragment has the VL and VH domains of a single antibody arm. A single-chain antibody (scFv) is an antibody in which the VL and VH domains are joined via a linker (e.g., a synthetic sequence of amino acid residues) to form a continuous protein chain, where the linker is long enough to allow the protein chain to fold back on itself and form a monovalent antigen-binding site.
[0090] The antibody is not particularly limited, but examples thereof include an anti-IL-6 receptor antibody, an anti-IL-6 antibody, an anti-glypican-3 antibody, an anti-CD3 antibody, an anti-CD20 antibody, an anti-GPIIb / IIIa antibody, an anti-TNF antibody, an anti-CD25 antibody, an anti-EGFR antibody, an anti-Her2 / neu antibody, an anti-RSV antibody, an anti-CD33 antibody, an anti-CD52 antibody, an anti-IgE antibody, an anti-CD11a antibody, an anti-VEGF antibody, and an anti-VLA4 antibody.
[0091] The product may be recovered by simply recovering the culture medium, or by recovering the liquid from which at least a portion of the cells have been removed using, for example, a filter or a centrifuge, and any known method can be used without particular limitation. If it is desired to improve the purity of the product, change the solvent, or change the form, for example, to make it into a powder, the culture medium or the liquid can be subjected to further treatment.
[0092] It is also possible to collect a portion of the culture medium during perfusion, or to use a filter or centrifuge on a portion of the culture medium during perfusion, and collect the liquid from which at least a portion of the cells have been removed.
[0093] The product can be purified by a purification process as described above in this specification. Separation and purification of the product can be performed using separation and purification methods commonly used for proteins, and as described above in this specification, the product can be separated and purified by appropriately selecting and combining chromatography columns such as affinity chromatography and other methods. Furthermore, when the product is an antibody, the antibody titer can also be measured using a commercially available analytical instrument such as Roche's Cedex Bio.
[0094] Examples of columns used in affinity chromatography include protein A columns and protein G columns. Chromatography other than affinity chromatography includes, for example, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography. These chromatographies can be performed using liquid phase chromatography such as HPLC (high performance liquid chromatography) or FPLC (fast protein liquid chromatography).
[0095] The product can be modified or partially depeptidized by treating it with an appropriate polypeptide-modifying enzyme before or after purification, such as trypsin, chymotrypsin, lysyl endopeptidase, protein kinase, or glucosidase.
[0096] The products produced by the present invention can be used in, for example, biopharmaceuticals and regenerative medicine.
[0097] The present invention will be explained in more detail with reference to the following examples, but the present invention is not limited to these examples.
[0098] <Establishment of antibody-producing cells> Vectors containing nucleic acid sequences encoding Rituximab, Denosumab, Blosozumab, Anti-hMUC1, or Emicizumab were constructed, and the constructed vectors were each introduced into CHO-DG44 cells to produce CHO cell A, CHO cell B, CHO cell C, CHO cell D, and CHO cell E expressing the respective antibodies. The vectors were constructed and introduced into the cells in accordance with Example 2 of JP-A-2016-517691. CHO cells producing monoclonal antibodies were prepared as described above and used in the following experiments.
[0099] [Perfusion Culture Experiment] In the examples and comparative examples, experiments were carried out using the cell culture device shown in Figure 1. The target cell density for antibody-producing CHO cells was set at a viable cell density (e.g., 120 x 10 6 The cells were grown to a cell density of 1000 cells / ml and cultured while maintaining that cell density. The culture period was continued for a total of 34 days unless the hollow fiber MF membrane became clogged. If the hollow fiber MF membrane became clogged, the culture was discontinued. The specific experiment was carried out as follows.
[0100] 1.3 L of medium was placed in a 3 L fermenter (Biostat (registered trademark)) manufactured by Sartorius. Each of the media A to E listed in Table 1 was prepared with reference to the replacement media in Table 2 of JP-A-2000-517188, and poloxamer was added to the concentrations listed in Table 1. The poloxamer used in the medium was Kolliphor (registered trademark) P188 Geismar manufactured by BASF. 0.5 x 10 6 CHO cells were seeded at 100 cells / ml. The agitation speed was 160 rpm, and air was supplied from above at 38 ml / min and CO 2 2 ml / min from the bottom of the culture tank through a sparger installed in the culture tank so that the oxygen concentration in the culture solution was 80%. 2 was automatically controlled and supplied.
[0101] After culturing for 2 days after seeding, the cell culture medium was continuously supplied with a perfusion ratio of 0.6 vvd, and the collected solution was continuously filtered using ATF2 (manufactured by Repligen). On the 5th day, the perfusion ratio was changed to the predetermined perfusion ratio shown in Table 1 and maintained thereafter.
[0102] Thereafter, when the cell density reached the target viable cell density listed in Table 1, cell bleeding was performed while extracting a portion of the culture medium so as to maintain that cell density. Cell bleeding was performed automatically and continuously to maintain a constant cell density while monitoring the capacitance of the culture medium using a FUTURA sensor manufactured by ABER. The cells used, the antibody produced, the medium, the culture conditions, etc. were changed as shown in the examples and comparative examples in Table 1, and multiple levels were tested. Thereafter, the culture was continued, and the evaluations described below were performed.
[0103] For 50 L cultivation, 50 L of medium was added to a Thermo Fisher Hypeforma 50 culture vessel, the agitation speed was set to 250 rpm, and the air flow rate from the top was set to 0.475 L / min + CO 2 The culture was carried out under the same conditions as the 1.3 L culture, except that the flow rate was 0.025 L / min and ATF4 manufactured by Repligen was used.
[0104] <Method for Automatic Cell Bleed Control> When cell bleeding was performed automatically, a FUTURA sensor manufactured by ABER was used to monitor the capacitance of the culture solution while automatically and continuously performing cell bleeding. Specifically, this was performed using the following method. (1) A target capacitance was set. (2) A weight control value for the culture tank was set. (3) The capacitance of the culture solution was measured at intervals of 0.1 s or less. (4) When the capacitance of the culture solution exceeded the target, the pump that extracts the culture solution was operated at a speed of 0.3 vvd to 3 vvd. (5) The culture medium was automatically supplied into the culture tank while measuring the weight of the culture tank so that the volume of the culture solution remained roughly constant. (6) When the capacitance of the culture solution fell 0.01% or more below the target, the pump that extracts the culture solution was stopped.
[0105] <Measurement and evaluation methods> (1) Measurement of cell density The culture medium was removed from the culture vessel and measured using a Beckman Coulter Cell Viability Analyzer Vi-cell XR. The Vi-cell software used was Vi-cell XR2.04, and the measurement parameters were set as follows: Min diameter: 6 μm Max diameter: 50 μm Dilution: cell density of 100 × 10 5 When the cell density was 100 x 10 cells / mL or less, the sample was not diluted and the measurement was performed at a dilution of 1. 5 For concentrations of 0.1 to 1.5 cells / mL, the sample was diluted 10 times and measured at a dilution of 10. Cell brightness: 85% Cell sharpness: 100 Viable cell spot brightness: 75% Viable cell spot area: 5% Minimum circularity: 0 Decluster degree: Medium
[0106] Measurement was carried out once a day using the above method.
[0107] (2) Measurement of antibody concentration in culture medium and permeate A sample of the culture medium was taken from the culture vessel, and the cells were filtered through Whatman (Pore Size 0.2 μm, 25 mm Diameter) manufactured by Cytiva. The filtrate was then measured using Cedex Bio manufactured by Roche. After sampling, the permeate was directly measured using Cedex Bio manufactured by Roche. Measurement was performed once a day using the above method.
[0108] (3) Measurement of poloxamer concentration in culture medium A culture medium sample was extracted from the culture vessel, and the cells were filtered using a Cytiva Whatman filter (Pore Size 0.2 μm, 25 mm diameter). The filtrate was collected. 1.17 g of maleic acid (special reagent grade, Fujifilm Wako Pure Chemical Industries, Ltd.) was added to 50 ml of deuterium oxide (Cambridge Isotope Laboratories) and dissolved. 0.4 ml of heavy water containing maleic acid was added to 1.6 ml of heavy water containing maleic acid, in which 20, 50, 100, and 200 mg of Kolliphor P188 (BASF) were dissolved, respectively. 1H NMR (400 MHz, Ascend 400, Bruker) was measured with an integrated total of 64 times. Using the maleic acid peak at 6.2 ppm as the standard, a calibration curve is drawn using poloxamer peak 1 (around 0.8-1.1 ppm) and peak 2 (around 3.4-3.5 ppm). 0.4 ml of culture supernatant is added to 1.6 ml of maleic acid-containing heavy water, and 1H NMR is measured at an integrated frequency of 64 times, and quantification is performed from the area ratio of peak 1 or peak 2 to maleic acid. Either peak 1 or peak 2 is used depending on the level of impurities.
[0109] (4) Evaluation of hollow fiber MF membrane clogging To evaluate clogging of the hollow fiber MF membrane, "1. ATF reciprocating dynamic pressure" was measured to evaluate clogging of the flow path of the hollow fiber, and "2. MF membrane permeability of antibody" was measured to evaluate clogging of the pores of the hollow fiber.
[0110] 1. ATF reciprocating pressure (evaluation of clogging of hollow fiber flow passage) A pressure gauge is installed below the ATF membrane, i.e., above the diaphragm, to measure the pumping and suction pressure of the ATF diaphragm pump (P In ), and a pressure gauge for measuring the outlet pressure of the ATF membrane is installed on the top of the ATF membrane (P Re ), and a pressure gauge for measuring the permeation pressure was installed on the permeation side of the ATF (P Pe Before running the ATF, each pressure gauge was zero-calibrated with the atmosphere, and then the ATF was run. In The maximum value of P In-max , the minimum value is P In-min , P Re The maximum value of P Re-max, the minimum value is P Re-min The ATF reciprocating pressure was recorded daily. In-max -P Re-max When the reciprocating pressure of the ATF exceeded 5 psi, it was determined to be blocked and the culture was discontinued.
[0111] 2. Antibody permeability through MF membrane (evaluation of clogging of hollow fiber pores) The antibody permeability through the MF membrane was evaluated by CP / CB×100 [%], where CB is the antibody concentration in the culture medium and CP is the antibody concentration in the permeate.
[0112] <Evaluation> On the final day of culture, evaluation was performed based on (1) ATF reciprocating pressure, (2) antibody permeability through the MF membrane, and (3) titer, and a comprehensive evaluation was performed based on each result.
[0113] When the hollow fiber MF membrane reached the clogging criterion, the culture was discontinued and that day was designated as the final day of culture. If the hollow fiber MF membrane did not become clogged, the culture was continued until day 34, which was designated as the final day of culture. Table 2 shows the measurement results on the final day of culture.
[0114] (1) ATF reciprocating pressure D: If the ATF reciprocating pressure reaches the blocking criterion by the 34th day C: If the ATF reciprocating pressure is 4 psi or more and 5 psi or less on the 34th day B: If the ATF reciprocating pressure is 3 psi or more and less than 4 psi on the 34th day A: If the ATF reciprocating pressure is less than 3 psi on the 34th day
[0115] (2) Antibody MF membrane permeability C: When the antibody MF membrane permeability on the final day of culture is less than 50% B: When the antibody MF membrane permeability on the final day of culture is 50% or more but 70% or less A: When the antibody MF membrane permeability on the final day of culture is more than 70%
[0116] (3) Titer Titer was calculated by multiplying the antibody concentration in the permeate by the perfusion ratio of that day, and the unit was g / L / day. C: Titer is less than 1.0 g / L / day B: Titer is 1.0 g / L / day or more and 1.5 g / L / day or less A: Titer exceeds 1.5 g / L / day
[0117] (4) Overall evaluation D: If there is a D rating C: If there is no D rating and there is one or more C ratings B: If all ratings are B or higher and there is one or less A ratings A: If all ratings are B or higher and there are two or more A ratings
[0118] The measurement results and evaluations for each Example and Comparative Example are shown in Table 2. The measurement results of viable cell density for Example 1 and Comparative Example 1 are shown in Figure 2. The measurement results of ATF reciprocating pressure for Example 1 and Comparative Example 1 are shown in Figure 3. The measurement results of antibody permeability for Example 1 and Comparative Example 1 are shown in Figure 4. The measurement results of titer for Example 1 and Comparative Example 1 are shown in Figure 5.
[0119]
[0120]
[0121] 1 Sparger air supply pipe 2 Air supply pipe 3 Culture medium supply pipe 4 Exhaust pipe 5 Exhaust filter 6 Sampling pipe 7 Bleeding pipe 8 Capacitance sensor 9 Dissolved oxygen sensor 10 Cultivation vessel 11 Sparger 12 Stirring blade 13 Perfusion device 14 Flow of permeate 15 Culture medium supply pump 16 Delivery pump 17 Pressure gauge 18 Diaphragm pump 19 Foam
Claims
1. A method for producing a product, which comprises culturing cells in a culture medium, wherein at least one of the following is satisfied: 1.5P + 3C + 0.93S ≦ 378 (Equation 1) or P + 3.5C + 1.9V ≦ 29 (Equation 5), where P is the poloxamer concentration in the culture medium (g / L), C is the product concentration in the culture medium (g / L), S is the hydrophobicity index SAP value of the product, and V is the ratio of valine residues in the L-chain variable site of the product (%).
2. A method for producing the product described in claim 1, wherein the poloxamer concentration P (g / L) satisfies 1.5≦P≦15 (Equation 2).
3. The method for producing the product according to claim 1, wherein the product concentration C (g / L) satisfies 0.2≦C≦10 (Equation 3).
4. The method for producing the product according to claim 1, wherein the hydrophobicity index SAP value S satisfies the following formula: 300≦S≦394 (Formula 4).
5. The method for producing the product according to claim 1, wherein the ratio V (%) satisfies the following formula 6: 0≦V≦9.
6. The method for producing the product according to claim 1, wherein the culture is a perfusion culture.
7. The method for producing the product according to claim 6, wherein the perfusion culture includes a cell separation step of separating cells using a filtration membrane.
8. The method for producing the product according to claim 7, wherein the cell separation step is carried out in an ATF mode, which is alternating tangential flow.
9. The method for producing the product according to claim 6, wherein, in the perfusion culture, after a target viable cell density is reached in the culture, the product is produced for a certain period of time while maintaining the viable cell density substantially constant.
10. The constant viable cell density is 30 x 10 6 cells / ml or more 400×10 6 The method for producing the product according to claim 9, wherein the concentration of the product is less than 1000 cells / ml.
11. The method for producing the product according to claim 6, wherein the perfusion ratio in the perfusion culture is 0.3 or more and 3.0 or less.
12. A method for producing a product according to any one of claims 1 to 11, wherein the culture period is from 14 days to 200 days.
13. A method for producing the product according to any one of claims 1 to 11, wherein the cells are CHO cells.
14. A method for producing a product according to any one of claims 1 to 11, wherein the product is a protein.
15. The method of producing the product of claim 14, wherein the protein is an antibody.
16. A method for producing the product described in claim 15, wherein the light chain structure of the antibody is of the κ type.
Citation Information
Patent Citations
Serum-free mammalian cell culture medium and uses thereof
JP2000517188A
Method of expression
JP2016517691A
Methods of cell culture by continuous perfusion and alternating tangential flow
JP2007525984A
Continuous manufacturing process for bispecific antibody products
JP2021505182A
Method for preparing prefilled syringe formulation
WO2023058723A1
